arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ADMA BIOLOGICS, INC.

ADMA
$9.88 ▼ -0.17 (-1.74%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
16 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Bullish
auto_awesome

Analytical Summary

ADMA BIOLOGICS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $2.4B
Dividend Yield
Revenue Growth 19.6%
Op. Margin 37.5%
ROIC 28.0%
FCF / Share $0.12
Trailing P/E 15.9x
Price / Book 4.9x
FCF Yield 1.2%
Debt / Equity 0.15
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$510.17M
↑ +19.6%
Net Income Profit after all expenses
$146.93M
↓ -25.7%
Operating Margin Operating profit as % of sales
37.5%
↑ +15.1% 92th
FCF / Share Free cash flow per share
$0.12
↓ -75.4%
Long-Term Debt Long-term obligations
$72.14M
— -0.3%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
76
Returns
93
Financial Health
83
Cash Quality
29

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 72 quarters